Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$167.40−2.00 (-1.18%)
Close on Nov 13, 2026Market cap $17.02BP/E 24.8Yield –
Neurocrine Biosciences statistics
99 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 10, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 14.33
- 2.22
- P/OCF Ratio
- 15.97
- 12.99
Enterprise valuationIndustry
- EV / Sales
- 4.40
- 2.57
- EV / EBIT
- 18.35
- 19.31
- EV / FCF
- 15.66
- 22.27
Share statisticsIndustry
- Shares Change (YoY)
- 1.96%
- 10.8%
- Shares Change (QoQ)
- -0.30%
- 0.50%
- Float
- 100M
- 49M
- Shares Held by Insiders
- 1.20%
- 11.7%
- Shares Held by Institutions
- 99.5%
- 56.4%
Short sellingIndustry
- Short Interest
- 6M
- –
- Short Interest Change
- -8.48%
- -0.80%
- Short % of Float
- 5.88%
- 9.01%
- Short % of Shares Outstanding
- 5.81%
- 6.30%
- Days to Cover
- 5.40
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $186.12
- –
- 52-Week Low
- $122.14
- –
- 20-Day Moving Average
- $154.30
- –
- 50-Day Moving Average
- $148.58
- –
- 200-Day Moving Average
- $148.88
- –
- Average True Range (14)
- $5.51
- –
- Price Change (1 Week)
- 1.68%
- -1.15%
- Price Change (1 Month)
- 22.2%
- -4.87%
- Price Change (3 Months)
- 8.36%
- -21.0%
- Price Change (6 Months)
- 5.67%
- -20.6%
- Price Change (YTD)
- 18.0%
- -23.6%
- Price Change (1 Year)
- 14.0%
- -22.4%
- Price Change (3 Years)
- 49.0%
- -29.5%
- Price Change (5 Years)
- 90.2%
- -77.9%
- Price Change (10 Years)
- 205.6%
- -65.4%
- Average Volume (10 Days)
- 2M
- –
- Average Volume (20 Days)
- 1M
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 1.04
- 0.70
- Relative Strength Index (14)
- 64.4
- 43.4
- Volatility (1 Year)
- 35.2%
- 80.1%
- Beta (5 Years)
- 0.46
- 1.07
MarginsIndustry
- Pretax Margin
- 25.2%
- -11.6%
- EBITDA Margin
- 24.0%
- -27.7%
- FCF Margin
- 28.1%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- 20.4%
- -49.9%
- Return on Assets (ROA)
- 14.2%
- -40.6%
- Return on Invested Capital (ROIC)
- 26.6%
- -32.9%
- Return on Capital Employed (ROCE)
- 19.1%
- -37.9%
Financial positionIndustry
- Current Ratio
- 2.04
- 3.30
- Quick Ratio
- 1.72
- 2.39
GrowthIndustry
- Revenue Growth (YoY)
- 38.0%
- 6.82%
- Net Income Growth (YoY)
- 64.1%
- -14.4%
- EPS Growth (YoY)
- 61.2%
- -12.3%
- FCF Growth (YoY)
- 75.3%
- 6.85%
- Revenue Growth (3Y CAGR)
- 24.3%
- 2.25%
- Revenue Growth (5Y CAGR)
- 22.3%
- 6.41%
- EPS Growth (3Y CAGR)
- 44.1%
- 1.30%
- EPS Growth (5Y CAGR)
- 2.34%
- 3.78%
EfficiencyIndustry
- Asset Turnover
- 0.75
- 0.40
- Inventory Turnover
- 1.24
- 2.73
- Revenue Per Employee
- $2.06M
- $429.29K
- Profits Per Employee
- $390.28K
- -$689.41K
- Employee Count
- 1,800
- 74
- WACC
- 7.60%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- $932.10M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $737.90M
- $17.76M
- Net Cash Per Share
- $7.26
- $0.80
- Equity (Book Value)
- $3.88B
- $53.89M
- Book Value Per Share
- $38.16
- $1.50
- Tangible Book Value
- $1.19B
- $27.13M
- Working Capital
- $1.02B
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$26.10M
- -$1.00M
- FCF Per Share
- $10.23
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- 4.13%
- -21.8%
- FCF Yield
- 6.11%
- -9.44%
- Buyback Yield
- -0.08%
- -0.76%
- Shareholder Yield
- -0.08%
- 0.00%
Taxes and interestIndustry
- Income Tax
- $229.60M
- $73.00K
- Effective Tax Rate
- 24.6%
- 20.9%
Scores and fair valueIndustry
- Graham Number
- $76.07
- $19.34
- Graham Upside
- -54.6%
- -46.6%
- Altman Z-Score
- 7.44
- 0.23
- Piotroski F-Score
- 7
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NBIX | S&P 500 | Difference | NBIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.9% | -3.0% | +26.9 pts | ||
| 3 months | +11.0% | -2.8% | +13.8 pts | ||
| Year to date | +18.0% | +11.5% | +6.5 pts | ||
| 1 year | +16.1% | +13.5% | +2.7 pts | ||
| 3 years | +51.8% | +77.7% | −25.9 pts | +14.9% | +21.1% |
| 5 years | +90.2% | +72.6% | +17.6 pts | +13.7% | +11.5% |
| 10 years | +218.4% | +308.2% | −89.8 pts | +12.3% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
6M NBIX shares were sold short on Oct 30, 2026, down 8.5% from the previous report, or 5.88% of the shares available to trade. At recent volumes it would take 5.4 days to buy them back. Over the last 20 sessions, 56.8% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 5,900,825 | -8.5% | 1,093,287 | 5.4 |
| Oct 15, 2026 | 6,447,491 | +10.2% | 1,418,632 | 4.5 |
| Sep 30, 2026 | 5,853,128 | +17.9% | 1,476,037 | 4.0 |
| Sep 15, 2026 | 4,964,907 | -1.8% | 924,045 | 5.4 |
| Aug 31, 2026 | 5,056,144 | +11.1% | 1,086,635 | 4.7 |
| Aug 14, 2026 | 4,551,075 | +3.7% | 1,329,597 | 3.4 |
| Jul 31, 2026 | 4,390,083 | -17.7% | 1,456,278 | 3.0 |
| Jul 15, 2026 | 5,334,688 | -3.5% | 1,086,810 | 4.9 |
| Jun 30, 2026 | 5,530,854 | -2.8% | 1,315,407 | 4.2 |
| Jun 15, 2026 | 5,690,488 | +2.9% | 1,128,101 | 5.0 |
| May 29, 2026 | 5,529,509 | +7.1% | 1,114,763 | 5.0 |
| May 15, 2026 | 5,160,707 | -13.9% | 1,400,192 | 3.7 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?